NCT05540275View on ClinicalTrials.gov

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 5, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Recurrent Glioblastoma
Interventions
DRUG

Tislelizumab plus Bevacizumab

200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks

Trial Locations (1)

450003

Henan Provincial People's Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Provincial People's Hospital

OTHER